Search results
Kirill Vesselov's Resources Unveil New Recovery Features in Boca Raton
Digital Journal· 9 hours agoSkill Development for Relapse Prevention: Focuses on developing coping mechanisms and relapse...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 22 hours agoThe regulatory body approved Breyanzi for the treatment of adult patients with relapsed or...
Steven Tyler Joins the Black Crowes Onstage in London Months After Fracturing Larynx
People via Yahoo News· 19 hours agoIn April, Aerosmith announced a new set of dates that will resume later this year and run until...
Kristen Bell Shares Parenting Rule She And Dax Shepard Have Related To Fights
Cinema Blend· 22 hours agoBecause while it's a dream that offers exciting opportunities, it can also make one's personal life...
If Stuart shuns alcohol and drug rehab center, where will its patients end up instead?
TCPalm | Treasure Coast Newspapers via Yahoo News· 6 hours agoIn any case, addicts seem unlikely to congregate around the one place in town where they know they...
Is It Time to Switch from Zoloft to Prozac? How to Tell
MediaFeed via AOL· 2 days agoJust as it takes time for your brain to gradually adjust to a new medication, it takes time to...
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
Morningstar· 1 day agoBristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR-T cell therapy Breyanzi for adults with relapsed or refractory follicular lymphoma ...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
WJTV Jackson· 2 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...
FDA Approves Tarlatamab for Extensive-Stage SCLC
Medscape· 1 day agoContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.
Precigen Reports First Quarter 2024 Financial Results and Business Updates
WRBL Columbus· 3 days ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation ...